Recurrence-free survival was numerically higher with adjuvant pembrolizumab, but difference was not significant. HealthDay News — For patients with resected Merkel cell carcinoma (MCC), adjuvant ...
A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's immune system to target and eliminate cancer cells appeared to reduce the ...
Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients with Merkel cell carcinoma after surgery. Though recurrence rates overall ...
A common pinworm medication may stop and reverse cancer growth in Merkel cell carcinoma, an aggressive form of skin cancer, according to research led by University of Arizona Cancer Center researchers ...
Incidence is increasing faster than melanoma, with typical presentation in the mid-70s and risk amplified by UV exposure, fair skin, immunosuppression, and MCPyV-associated oncogenesis. Accurate ...
In a prospective study of patients with stages I-III Merkel cell carcinoma (MCC), seropositivity for rising polyomavirus oncoprotein antibody titers conferred a 58% risk for recurrence at 12 months, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results